2024
RADT-12. DERIVING IMAGING BIOMARKERS FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA USING DEEP LEARNING
Zhu J, Hager T, Chadha S, Sritharan D, Weiss D, Hossain S, Osenberg K, Moore N, Aneja S. RADT-12. DERIVING IMAGING BIOMARKERS FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA USING DEEP LEARNING. Neuro-Oncology 2024, 26: viii74-viii74. PMCID: PMC11553274, DOI: 10.1093/neuonc/noae165.0296.Peer-Reviewed Original ResearchPrimary central nervous system lymphomaWhole-brain radiotherapyTreated with chemotherapyOverall survivalHigh-risk groupPatient phenotypesCentral nervous system lymphomaPCNSL treatmentRisk of neurocognitive side effectsImaging biomarkersC-statisticOne-year OSTwo-year OSNervous system lymphomaAssociated with improved outcomesLog-rank testNeurocognitive side effectsTime-dependent AUCBrain radiotherapySystem lymphomaTumor volumeTumor sizeRisk stratificationAnalyses assessed differencesSub-analysis
2023
Development and Validation of MRI Imaging Biomarkers for Prostate Cancer Using Deep Learning
Hossain S, Hossain S, Avesta A, Nene A, Maresca R, Aneja S. Development and Validation of MRI Imaging Biomarkers for Prostate Cancer Using Deep Learning. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e393. DOI: 10.1016/j.ijrobp.2023.06.1517.Peer-Reviewed Original ResearchBiochemical-free survivalSeminal vesicle invasionHigh-risk phenotypeExtraprostatic extensionProstate cancerHigh riskRadical prostatectomyProstate MRILower riskImaging biomarkersNon-invasive imaging biomarkersPost-treatment PSAUnderwent radical prostatectomyIntermediate-risk patientsDiscriminatory abilityLog-rank testAggressive prostate cancerProstate cancer patientsProstate cancer phenotypePersonalization of treatmentMATERIAL/METHODSGood discriminatory abilityMedian followTreatment escalationFree survival